Immunoglobulin characteristics and RNAseq data of FcRL4+ B cells sorted from synovial fluid and tissue of patients with rheumatoid arthritis

Data in Brief 13 (2017) 356–370

Contents lists available at ScienceDirect

Data in Brief journal homepage: www.elsevier.com/locate/dib

Data Article

Immunoglobulin characteristics and RNAseq data of FcRL4 þ B cells sorted from synovial fluid and tissue of patients with rheumatoid arthritis Khaled Amara a, Elizabeth Clay b, Lorraine Yeo b, Daniel Ramsköld a, Julia Spengler b, Natalie Sippl a, James Cameron b, Lena Israelsson a, Philip J. Titcombe a, Caroline Grönwall a, Ilfita Sahbudin b, Andrew Filer b, Karim Raza b,c, Vivianne Malmström a,1, Dagmar Scheel-Toellner b,n,1 a Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, SE17176 Solna, Stockholm, Sweden b Rheumatology Research Group, RACE AR UK Centre of Excellence in RA Pathogenesis, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK c Department of Rheumatology, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK

a r t i c l e i n f o

abstract

Article history: Received 14 March 2017 Received in revised form 24 May 2017 Accepted 1 June 2017 Available online 7 June 2017

This manuscript is a companion paper to Amara et al. [1]. Data shown here include detailed clinical characteristics from anonymized patients, the Ig subclass data generated from B cells sorted from four individual patients, tables detailing variable gene region sequences from sorted cells linked to the patient information and the sequence yields from individual patients. Furthermore a URL link to the RNAseq datasets submitted to GEO is included. & 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Keywords: B cells FcRL4 Rheumatoid arthritis IRTA1

DOI of original article: http://dx.doi.org/10.1016/j.jaut.2017.03.004 Corresponding author: Rheumatology Research Group, Institute of Inflammation and Ageing. College of Medical & Dental Sciences, University of Birmingham Research Laboratories, Queen Elizabeth Hospital, Birmingham, B15 2WD. Tel.: þ 44 121 371 3220 E-mail address: [email protected] (D. Scheel-Toellner). 1 VM and DST contributed equally. n

http://dx.doi.org/10.1016/j.dib.2017.06.009 2352-3409/& 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

K. Amara et al. / Data in Brief 13 (2017) 356–370

357

Specifications Table Subject area More specific subject area Type of data How data was acquired Data format Experimental factors

Experimental features

Data source location Data accessibility Related research article

Immunology B cells in Rheumatoid Arthritis 1 figure, 3 tables, url to data Sequencing, patient clinical characteristics linked to experimental data Analyzed, raw FcRL4 þ and FcRL4- B cells were sorted from synovial fluid and tissue from RA patients. Synovial fluid derived B cells were analysed for their gene expression profile by RNAseq. Immunoglobulin variable region genes from single sorted B cells were sequenced and expressed as components of recombinant monoclonal antibodies. These were investigated for their reactivity with autoantigens. Data shown here include detailed clinical characteristics from anonymized patients, the Ig isotype data generated from B cells sorted from four individual patients, tables detailing variable gene region sequences from sorted cells linked to the patient clinical characteristics and the sequence yields from individual patients. We also supply a URL link to the RNAseq datasets submitted to GEO. Birmingham UK https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc ¼GSE94897 1) Amara K, Clay E, Yeo L, Ramsköld D, Spengler J, Sippl N, Cameron JA, Israelsson L,Titcombe PJ, Grönwall C, Sahbudin I, Filer A,Raza K, Malmström V, Scheel-Toellner D. B cells expressing the IgA receptor FcRL4 participate in the autoimmune response in patients with rheumatoid arthritis. J Autoimmun. 2017. pii: S08968411(16)30396-1. doi: 10.1016/j.jaut.2017.03.004 [Epub ahead of print]

Value of the data

 First RNAseq dataset from FcRL4 þ and FcRL4- B cells sorted from the synovial fluid of patients with  

rheumatoid arthritis. This will be valuable to researchers interested in the regulation of B cell subpopulations and their functional role in RA. Ig subclass distribution in FcRL4 þ and FcRL4- B cells infiltrating the rheumatoid joint. This gives important information of the potential origins of these cells and their potential function in the joint. The tables linking variable region sequences, gene usage, Ig isotypes and reactivity with citrullinated autoantigens give insight into the immune response to citrullinated proteins on a single cell basis.

1. Data The data shown in this manuscript have been generated in a study of FCRL4 þ and FcRL4- B cells infiltrating the synovial fluid and synovial tissue of RA patients. They include a link to the GEO dataset of RNAseq gene expression profiles of these cells. Furthermore, the Ig isotype distribution of the B cells for these populations is shown for four individual patients in Fig. 1. Table 1 gives detailed clinical characteristics from the anonymized patients. These are linked to the data shown in Table 2, detailing variable gene region sequences from sorted cells, the isotype usage and reactivity with citrullinated proteins of these individual cells. Table 3 displays the number of sequences and recombinant monoclonal antibodies generated from FcRL4 þ and FcRL4- B cells from individual patients.

358

K. Amara et al. / Data in Brief 13 (2017) 356–370

Fig. 1. Ig subclass distribution determined in single sorted FcRL4 þ and FcRL4- B cells in four individual patients.

2. Experimental design, materials and methods More detailed information can be found in Ref. [1]. 2.1. Experimental design FcRL4 þ and FcRL4- B cells were sorted from synovial fluid and tissue from RA patients. Synovial fluid derived B cells were analysed for their gene expression profile by RNAseq. Immunoglobulin variable region genes from single sorted B cells were sequenced and expressed as components of recombinant monoclonal antibodies. These were investigated for their reactivity with autoantigens. Amplification of sections of Ig constant regions was used to identify Ig isotype usage. 2.2. Materials and methods Cells from 4 SF and 2 ST samples were stained for CD19 and FcRL4 and sorted either as single cells or as cell populations. Individual IgH and IgL chain gene rearrangements were PCR-amplified independently. For identification of Ig isotypes, amplification of IgH chains with reverse primers specific for the constant regions of all human Ig classes and sequencing was used. Cloning of the Ig genes into expression vectors and antibody production and purification were performed. Antibody reactivity against citrullinated peptides was determined by ELISA. For gene expression analysis RNA sequencing was carried out on sorted FcRL4 þ and FcRL4- B cells from 4 SF samples. Preamplification prior to Illumina Truseq library preparation was performed using the SMARTer amplification using olig(dT)

Table 1 Clinical characteristics of RA patients who provided synovial fluid or synovial tissue. RF, rheumatoid factor; CCP, cyclic citrullinated peptide; CRP, C reactive protein; ESR, erythrocyte sedimentation rate, DAS28, disease activity score 28, TJC, tender joint count, SJC swollen joint count, VAS visual analog score. Hydroxychlor., Hydroxychloroquine. NA not available. Sample Diagnosis Gender Age (yrs)

Age at Dis. Dur. RF onset of RA (yrs)

CCP CRP ESR DAS 28 TJC ESR (28)

SJC (28)

VAS gen. health

Figures

Current disease modifying therapy

1

ST

RA

F

69

27

42

NA

pos

0

18

5.6

12

3

80

Adalimumab

2

ST

RA

M

70

55

15

pos

pos

11

24

3.86

2

1

40

3

SF

RA

M

72

72

0.23

neg neg

23

30

6.0

11

14

49

4

SF

RA

F

52

41

12

neg neg

0

38

5.4

5

2

89

5

SF

RA

F

40

40

0.23

pos

pos

8

9

5.9

19

8

84

6

SF

RA

F

49

38

11

pos

na

3

15

3.1

2

2

0

7 8 9 10 11 12 13 14 15

SF SF SF SF SF SF SF SF SF

RA RA RA RA RA RA RA RA RA

M F F F M F F F F

68 60 44 60 39 70 60 60 63

56 51 41 57 34 68 57 29 62

12 9 3 3 5 2 3 31 1

NA NA neg pos NA pos pos neg pos

NA pos neg pos NA neg pos pos pos

19 45 13 20 NA 142 122 57 30

15 13 29 55 NA 21 104 28 60

NA NA 4.95 7.05 NA 4.8 5.88 6.75 4.13

NA 6 7 15 NA 5 2 16 1

NA NA 3 10 NA 2 4 11 2

NA NA 45 85 NA 73 91 89 22

1A, 1B, 3B, 3C, 1A, 1B, 3B, 3C 1A, 1B, 3B, 3C 1A, 1B, 3B, 3C 1A, 1B, 3B, 3C, 1A, 1B, 3B, 3C 1C 1C 1C 1C 1C 1C 1C 1C 1C

16 17

SF SF

RA RA

M F

54 77

54 68

0.23 9

neg neg neg neg

88 71

58 62

7.39 NA

23 NA

12 NA

93 NA

1C 1C

18

SF

RA

M

72

56

16

pos

pos

5

15

13

NA

NA

NA

5A, 5B

19 20 21

SF SF SF

RA RA RA

F F F

32 52 46

31.2 49 35

0.8 3 9

pos pos pos

pos pos pos

15 13 NA

48 34 NA

5.9 6.54 NA

8 14 NA

6 10 NA

93 78 NA

5A, 5B 5A, 5B 5A, 5B

2A, 2B, 3A, 4A, 4B 2A, 2B, 3A, 2A, 2B, 3A, 2A, 2B, 3A, 2A, 2B, 3A, 4A, 4B 2A, 2B, 3A,

Etanercept, Methotrexate, Hydroxychlor. Nil Methotrexate Tocilizumab Hydroxychlor. Etanercept, Methotrexate Methotrexate Methotrexate Methotrexate Nil Etanercept Prednisolone Sulfasalazine Prednisolone Methotrexate, prednisolone Nil Methotrexate, Prednisolone Etanercept, Methotrexate, Hydroxychlor. Nil Nil Methotrexate, Hydroxychlor.

K. Amara et al. / Data in Brief 13 (2017) 356–370

Patient identifier

359

360

Table 2 Sequence data and reactivity of monoclonal antibodies from FcRL4 þ and FcRL4- B cells from RA patients. Patient id Clone 1

ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST

(CD19þ FcRL4 þ) (CD19þ FcRL4 þ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ ) (CD19þ FcRL4 þ )

VH

DH

JH Ig SC VH-mut. VH CDR3 (aa)

( þ) Length CCP2 CEP-1 cit-vim 60-75 cit-fib 36-52

3-33 3-15 3-11 5-51 3-33 1-18 3-23 3-30-3 1-46 1-69 3-30 4-59 4-4 1-2 1-18 3-23 3-53 5-51 3-23 3-21 3-21 4-34 3-23 4-30-4 3-48 5-51 1-69 3-9 4-34 3-11 1-69 5-10-1 3-30 3-48 4-30-4 4-38-2 3-21 4-38-2 3-49

2-2 2-2 4-17 3-22 6-13 3-10 6-13 3-22 3-3 2-8 4-11 6-13 3-10 3-9 1-26 2-2 3-3 6-13 2-15 3-9 2-15 1-26 3-10 3-3 3-3 4-23 5-12 1-26 2-15 5-12 1-1 3-10 2-8 3-3 3-10 6-13 2-8 3-3 3-3

6 6 4 3 4 5 5 4 3 4 4 6 3 4 6 6 4 6 6 4 6 4 1 5 4 6 4 4 4 3 4 4 6 4 4 3 4 4 4

3 1 2 2 1 2 2 1 1 2 4 1 1 2 1 3 2 2 3 3 3 4 4 1 2 2 1 2 4 2 2 2 1 2 1 2 1 2 2

IgG1 IgG1 IgA1 IgA1 IgA1 IgA1 IgA1 IgG1 IgA1 IgG1 IgG1 IgA1 IgG1 IgG1 IgG3 IgA1 IgG1 IgA2 IgA1 IgA1 IgG2 IgA1 IgA1 IgG2 IgG1 IgA1 IgG1 IgA1 IgG1 IgA1 IgA1 IgA2 IgA1 IgA1 IgG1 IgA1 IgG1 IgA1 IgA1

6 29 10 1 10 15 23 35 20 17 18 21 8 8 26 12 14 22 15 20 25 29 1 36 31 19 12 24 6 19 34 16 21 26 0 31 19 22 26

SRVGRVPDAVRYYFYGDV ATDVFRTVVPVAIYSFYGLAV ARGRWGLYGDYIFDS ARPHYYDSLDAFDI AREEGTGIVATDTESDFFDS ARRPDSSQYSNWIDP AKDDSPIATHSSWDS VRGYCSSLSCSSFDS ARAEGAVTIDDAFDI ARHCNNGLCFYYFDY VKDAYRTQSPHFNNR ARAGSWFLYGMDV TSPQGGPGSYPHDAFDV CARLRQDFDLLTGYQLGSYYFDY AKDQWEAYYGLDV ARGKARYQLPTYFYYGMDV ARAAVDFWSGYHLEY TRLGSWYLHYYGVDV AKRVVVASNHGYYSMDV ARDYDVFTGYPSHFFDH ARDRVDIVVKEPNFYYGVDV ANRRRYTTRFYFDF AKDRGVLRYFDWLH ASSGFFGQPYNWFDR ARDTRDFWSGYYTYYFDY ARLGKTTTVTSPYYYYYGMDV ARDSGYDEGYYFDY AKASGLTGSFYPLDH ARGGHRKYCSGGSCIYYFDY ARDDTVAFKDALDI ARERALCAEGCPPGDD ARVRTYYSAGTYPFDS AKAWGQLAGFALYFYGLDV ARINYDYWSDYARFLDS AFHLGEYGSGSYYDLDY ARDRGYSTNWFLGFDV AKPTVVYGPIDY AREFEHFGSGYFPVDY NSRSGFGVVAPEIDH

18 21 15 14 20 15 15 15 15 15 15 13 17 23 13 19 15 15 17 17 20 14 14 15 18 21 14 15 20 14 16 16 19 17 17 16 12 16 15

pos

pos

pos

neg

neg neg neg neg neg

neg neg neg neg neg

neg neg neg neg neg

neg neg neg neg neg

neg neg

neg neg

neg neg

neg neg

neg

neg

neg

neg

neg

pos

pos

neg

pos neg neg

neg neg neg

neg neg neg

neg neg neg

neg neg

neg pos

neg neg

neg neg

neg neg

neg neg

neg neg

neg neg

K. Amara et al. / Data in Brief 13 (2017) 356–370

146 þ.A06 146 þ.A07 146 þ.A08 146 þ.A09 146 þ.A10 146 þ.A11 146 þ.A12 146 þ.B01 146 þ.B02 146 þ.B03 146 þ.B04 146 þ.B05 146 þ.B06 146 þ.B08 146 þ.B12 146 þ.C01 146 þ.C04 146 þ.C05 146 þ.C06 146 þ.C08 146 þ.C09 146 þ.C10 146 þ.D07 146 þ.D08 146 þ.D09 146 þ.D10 146 þ.E01 146 þ.E02 146 þ.E04 146 þ.E05 146 þ.E06 146 þ.E07 146 þ.E08 146 þ.E12 146 þ.F01 146 þ.F02 146 þ.F04 146 þ.F08 146 þ.F09

cell origin

(CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ

FcRL4 þ ) FcRL4 þ ) FcRL4 þ ) FcRL4 þ ) FcRL4 þ ) FcRL4 þ ) FcRL4 þ ) FcRL4 þ ) FcRL4 þ ) FcRL4 þ ) FcRL4 þ ) FcRL4 þ ) FcRL4 þ ) FcRL4 þ ) FcRL4 þ ) FcRL4 þ ) FcRL4 þ ) FcRL4 þ ) FcRL4 þ ) FcRL4 þ ) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-)

3-23 4-59 3-43 3-20 4-31 1-46 3-30 4-30-4 1-3 3-33 1-18 1-18 3-23 1-3 3-30 4-61 3-30 4-34 4-34 1-18 3-30 3-9 5-10-1 4-59 3-15 4-4 1-18 1-46 1-46 4-34 3-23 3-48 4-30-4 4-30-4 3-7 3-7 4-34 3-74 3-11 4-59 3-30-3 3-11 5-10-1 1-3

1-26 3-3 6-19 1-26 3-3 1-14 7-27 3-16 2-15 5-24 6-19 3-16 2-2 1-26 3-9 3-22 1-26 6-13 2-21 3-3 4-17 3-3 3-10 2-15 4-17 2-15 3-9 3-10 3-3 1-26 2-8 3-22 3-22 3-22 6-13 6-13 2-15 2-2 4-17 4-11 3-9 3-10 2-15 2-8

4 3 4 4 5 6 4 5 4 4 3 4 4 6 6 2 5 5 6 5 4 5 5 3 4 4 4 3 6 4 4 4 4 4 6 6 4 6 4 4 4 6 5 4

IgA1 IgA1 IgM IgA1 IgG1 IgG1 IgG1 IgG1 IgG1 IgA1 IgA1 IgG1 IgA1 IgM IgG3 IgG2 IgG1 IgA1 IgG1 IgA1 IgG1 IgG1 IgA1 IgA1 IgG1 IgG1 IgG1 IgA1 IgG1 IgA1 IgG1 IgG1 IgM IgG1 IgG2 IgA2 IgA1 IgG3 IgG1 IgA1 IgG1 IgG4 IgG1 IgA1

20 22 3 15 10 18 4 36 14 31 4 10 27 1 33 3 26 9 8 14 13 14 31 7 17 17 30 20 29 32 22 0 3 26 25 31 8 11 16 25 13 26 19 25

ATDGEGVLFDE ARVMTVFGVVPDAFDI AKDISSTGWEYCFEN AKPSRVGAAADADY AREGVHATTFGMIDDQGWFDP ARVSPGIRDDMDV ARESGARWDVYFDY ARAPPETLRGIVGNWFDP VKDGGAGGANTFDH ARARRGDGYNQARYYYFDY ARGWYSRGGGMDV ARGWDPIVLPDYW AKSHLAHYVPVPAPFDF TRDLLDRGKYYRVAGHFYGMDV ARDGGENEIVTGYFGWSNKPHSVKYYHGMDV ARHVGRLRRDSFTTRRTTDAADDWHIDL AKQSATMGPNRQPR ARGFWDSGSWFDY ASKGGDSVGYHYYMDV ARGRPSTFGVVRGFDP TRATRVNGNLNTFDY AKDRFGELTDLTYVGWFDP ARLDTSVIRGYNWFDP ARHRGGSPTAFDI TTVDDYECHDY ARVSEAYFDPFYYDNN ARAPGSLRYYDWVSLYEEGDH TSPQGGPGSYPHDAFDV ARVTTFESGPNDFGVPDHFYYVLDV ANRRRCTTRFYFDF AKPLVYARLYFYYDLDY VRDSPGWGFRYYDY AAYPGDNSGRHLISPPFDN AAYGSYDRHLISPNPFYYDN VSQQVVPC VSGGLQQYDVVPC ARGGHRKYCSGGSCIYYFDY ARVQPQRVLVFYGMDV ARGAVTTPEYYFDY ARLDYSPAFIFDS ARGWERYYDWVAPGH ARGPSGMFGDLSPYFHYGVDV ARHGRGPSSWYDF ARSHQPYILLAGTPGD

0 1 1 2 2 2 2 2 2 4 2 1 3 5 5 8 3 1 2 3 2 2 2 3 1 1 3 1 2 4 2 2 2 2 0 0 4 2 1 1 3 2 3 2

11 16 15 14 21 13 14 18 14 19 13 13 17 22 31 28 14 13 16 16 15 19 16 13 11 16 21 17 25 14 17 14 19 20 8 13 20 16 14 13 15 21 13 16

neg

neg

neg

neg

neg neg neg neg

neg neg neg pos

neg neg neg pos

neg neg neg neg

neg neg

pos neg

neg neg

neg neg

neg

neg

neg

neg

neg

neg

neg

neg

neg neg neg neg

neg neg neg neg

neg neg neg neg

neg neg neg neg

neg neg neg neg neg neg

neg neg neg neg neg neg

neg neg neg neg neg neg

neg neg neg neg neg neg

neg

neg

neg

neg

neg

neg

neg

neg

neg neg

neg neg

neg neg

neg neg

neg

neg

neg

neg

361

ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST

K. Amara et al. / Data in Brief 13 (2017) 356–370

146 þ.F10 146 þ.F11 146 þ.F12 146 þ.G01 146 þ.G02 146 þ.G03 146 þ.G04 146 þ.G05 146 þ.G06 146 þ.G07 146 þ.G09 146 þ.G10 146 þ.G11 146 þ.G12 146 þ.H02 146 þ.H05 146 þ.H07 146 þ.H08 146 þ.H09 146 þ.H10 146-.A03 146-.A06 146-.A07 146-.B05 146-.B07 146-.B11 146-.B12 146-.C01 146-.C07 146-.C10 146-.D03 146-.D05 146-.D06 146-.D09 146-.E04 146-.E05 146-.E06 146-.E07 146-.E08 146-.E10 146-.E11 146-.F01 146-.F04 146-.F08

362

Table 2 (continued ) Patient id Clone 146-.F10 146-.F11 146-.G03 146-.G04 146-.G05 146-.G07 146-.H01 146-.H02 146-.H04

ST ST ST ST ST ST ST ST ST

(CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ (CD19þ

cell origin SF (CD19 þ SF (CD19 þ SF (CD19 þ SF (CD19 þ SF (CD19 þ SF (CD19 þ SF (CD19 þ SF (CD19 þ SF (CD19 þ SF (CD19 þ SF (CD19 þ SF (CD19 þ SF (CD19 þ SF (CD19 þ SF (CD19 þ SF (CD19 þ SF (CD19 þ SF (CD19 þ SF (CD19 þ SF (CD19 þ SF (CD19 þ SF (CD19 þ SF (CD19 þ SF (CD19 þ SF (CD19 þ SF (CD19 þ SF (CD19 þ SF (CD19 þ SF (CD19 þ

JH Ig SC VH-mut. VH CDR3 (aa)

( þ) Length CCP2 CEP-1 cit-vim 60-75 cit-fib 36-52

VH

DH

FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-)

5-10-1 4-31 3-66 1-18 3-48 3-20 4-59 3-23 3-11

2-15 3 4-23 4 4 6-19 2 5-18 3 3-22 4 2-21 4 3-22 5 3-22 4

IgA1 IgG2 IgG1 IgM IgM IgG1 IgA1 IgM IgG1

19 22 17 5 0 12 22 2 25

AKAASRFDTFDI TRGVIGLRGVPYYFDS RVDDTAVYYCARSPTGYDILTGPFDY ARAVAVNWYFDL ARGRKGYSYDAFDI ARGPPYYISSGYYFSFDS ARDDSLGGFDY AKYYDTSGSYKACDI ARGFYHDGTAYYHRNQSPFDH

2 2 2 1 3 1 1 2 5

12 16 26 12 14 18 11 15 21

FcRL4þ ) FcRL4þ ) FcRL4þ ) FcRL4þ ) FcRL4þ ) FcRL4þ ) FcRL4þ ) FcRL4þ ) FcRL4þ ) FcRL4þ ) FcRL4þ ) FcRL4þ ) FcRL4þ ) FcRL4þ ) FcRL4þ ) FcRL4þ ) FcRL4þ ) FcRL4þ ) FcRL4þ ) FcRL4þ ) FcRL4þ ) FcRL4þ ) FcRL4þ ) FcRL4þ ) FcRL4þ ) FcRL4þ ) FcRL4þ ) FcRL4þ ) FcRL4þ )

VH 4-39 3-13 4-39 1-69 4-59 3-48 3-33 3-74 1-18 4-59 5-51 3-33 3-33 5-51 4-34 4-59 3-21 1-69 1-2 4-30-2 1-69 3-66 1-69 3-15 3-15 3-9 3-33 1-18 3-74

DH 3-10 3-9 3-22 3-10 3-22 3-3 3-9 3-10 3-22 3-3 6-19 7-27 2-21 3-3 3-10 6-13 3-10 2-15 3-22 3-9 4-17 3-22 6-6 3-9 1-1 2-15 3-3 2-15 1-7

Ig SC IgG1 IgA1 IgG1 IgG1 IgG3 IgG4 IgG2 IgG1 IgA1 IgA1 IgA1 IgA1 IgA1 IgA1 IgA1 IgA1 IgA1 IgG2 IgG1 IgM IgG2 IgG3 IgG2 IgG1 IgG1 IgG2 IgG1 IgM IgG1

VH-mut. 6 16 2 12 13 4 8 6 2 3 4 16 1 0 7 7 10 6 7 1 4 4 5 5 4 9 8 4 7

VH CDR3 (aa) ARLGGGYYYGSGYTRFDP ATKPSHIYLRYFDWLLQGVRPLL ARYLREDYDISGLDY ARRGYYYDYVWGDFRLTGPIEGAFDI AADNYYDSSEYSPYSFDS ASDKYDSWSRYVPYYGLDV ARGPDILTGGFYFDY VRGDLWFVELLYG ARGSPYYYDSSGYYHYFDS ARDKSADTLEWYYYYYGMDV APQSGSGWPYFDY ARHRGVTGLLNEPGDY ARLLKTYCGGDCSLGY ARQYYDFWSDYYNSDYYYGMDV ARESHDHAELGYYYGMDV ASLPGSSTWFPFDY ARIRTKWFRRSSTMSSSFDY ARGRVPRIYYYYGMDV ARCDWGIYYYDSRAHGAFDF ARDQFFLAALDY AREDYGDDYYYYGMDV AREYNYDSSDAFDI ARSVQNLRYLGYYFDY TSSLVLRYFDWSTHSSDY TTALNWNWDYYDY VASYWRGYYFDY AKVAGYDFWSGPGGYYYSMDV ARDSGGSWLDP ARGGWGPRYNWNQGAVDY

( þ) 2 4 2 3 0 2 1 1 2 2 0 3 2 1 3 0 5 3 3 1 1 1 2 2 0 1 1 1 2

Length 18 23 15 26 18 19 15 13 19 20 13 16 16 22 18 14 20 16 20 12 16 14 16 18 13 12 21 11 18

JH 5 1 4 3 4 6 4 4 4 6 4 4 4 6 6 4 4 6 3 4 6 3 4 4 4 4 6 5 4

neg

neg

neg

neg

neg

neg

neg

neg

CCP2 CEP-1 cit-vim 60-75 cit-fib 36-52 neg pos neg neg neg neg

neg neg

neg neg

neg nrg

neg neg

neg neg

neg neg

neg neg

neg

neg

neg

neg

neg

neg

neg

neg

neg neg

neg neg

neg neg

neg neg

pos

pos

pos

neg

K. Amara et al. / Data in Brief 13 (2017) 356–370

Patient id Clone 5 153 þ.A04 153 þ.A08 153 þ.A09 153 þ.A10 153 þ.B05 153 þ.B08 153 þ.C03 153 þ.C04 153 þ.C06 153 þ.C09 153 þ.C10 153 þ.C12 153 þ.D01 153 þ.D06 153 þ.D08 153 þ.E01 153 þ.E03 153 þ.E04 153 þ.E05 153 þ.E07 153 þ.E11 153 þ.F02 153 þ.F04 153 þ.F07 153 þ.G01 153 þ.G07 153 þ.H01 153 þ.H02 153 þ.H06

cell origin

(CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ

FcRL4þ ) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-)

cell origin SF, CD19 þFcRL4 þ SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ

3-11 4-34 1-18 4-59 1-69 5-51 4-4 3-23 1-18 1-46 5-51 4-39 1-8 3-21 4-4 3-49 4-59 4-34 4-30 3-9 4-4 1-24 3-48 3-9 3-7 4-61 3-23 3-49 1-2 3-23 5-51 1-18 1-8 3-9

4-11 3-22 2-15 3-10 6-19 2-2 4-17 2-21 6-13 5-18 5-12 3-16 3-22 5-24 2-15 3-10 3-10 3-10 3-16 1-1 1-14 3-22 3-16 2-15 3-10 4-23 5-24 3-22 3-3 3-9 3-3 3-16 3-3 6-6

6 2 6 5 5 3 4 6 5 4 6 4 5 4 4 6 4 3 4 4 4 4 4 4 4 5 4 3 5 4 4 4 6 6

IgA1 IgA1 IgG1 IgG4 IgM IgG2 IgM IgG2 IgG3 IgG1 IgG2 IgG1 IgM IgA2 IgG1 IgG1 IgA1 IgA1 IgA1 IgA1 IgG1 IgA1 IgG1 IgM IgG1 IgG2 IgG1 IgG2 IgG3 IgM IgG1 IgG1 IgG4 IgG2

18 14 7 5 1 3 4 6 5 8 6 12 2 8 10 12 5 5 8 7 7 14 11 1 8 5 4 3 5 9 7 11 6 6

ARQSAYANYYYKGMDV ARGLTFSYYDSSGFGYYYWYFDL ARDRHCSGGTCYPYHYGMDV ARTTTIRGVINWFDP ARDFQRTSTVTRGIAVGSRFDP ARHLEYPHYVFDF ARGGIWNDYGDFYPYYFDY AKEDYHFGRVD ARDGAMGHPDFWQQLVASWFDP AKSRGYSYGYFDY ARLPHYDWYYYYAMDV ARRSVYDANFDF ARAPYYYDSSGYYRGWFDP ARDLVEMATIIGHISY ARVVSEAAYFDN SRVLRVVWGGRYYCMDV ARVIMFTMVRGVQYYFDY ARGREVIMVRGVMKGTEAFDI ARGGREMLTIGGVVLSAFDF VKDITWNRLWVFDS ARDKGNQPFFDY ATVQNYFDSSGRVTPKSDFDY AGGRSYDYFDY AASYWRGYYFDY ARGESGGWFGEWVDY ATYAMGYGGKGS AAPPDGYNSEGYFDY CREEKDYYDRPRDAFDI ARGIGFNSWSGYPNWFDL ATVSGWGGH ARHERYYDFWSGYYTEFDY ARDLGFTFGGVMGY ARGINDFWSDYGMDV AKDKWKLAGASGGMDV

2 1 4 2 4 3 1 3 2 2 2 2 2 2 1 3 2 4 2 2 2 2 1 1 1 1 0 4 1 1 3 1 1 3

16 23 20 15 22 13 19 11 22 13 16 12 19 16 12 17 18 21 20 14 12 21 11 12 15 12 15 17 18 9 19 14 15 16

VH 4-31 1-69 3-49 1-69 1-69 4-30-4 5-10-1 3-30 1-69

DH 4-17 5-24 3-22 5-18 5-24 3-22 3-22 1-26 6-19

JH 3 6 3 4 4 3 1 4 4

Ig SC IgG1 IgA1 IgG1 IgG2 IgG1 IgA1 IgA2 IgG2 IgA1

VH-mut. 6 21 12 17 18 27 22 5 13

VH CDR3 (aa) ARGLDTHYGDYELDAFDI TREISAKGANYNYYGMDV ARDRWIVVVPEGGASDI AREEAVDTAMLWYY CAREGLYIATAFFDL ATQSLGSSGYYRAFDI AKDLLHFPYYYDSSDYYWPAVYFDL ASGPRSGRKDYFDD VRGSSGWNFDH

( þ) 2 2 2 1 1 1 2 3 2

Length 18 18 17 14 15 16 25 14 11

neg

neg

neg

neg

neg

neg

neg

neg

neg neg

neg neg

neg neg

neg neg

neg

neg

neg

neg

neg

neg

neg

neg

neg

neg

neg

neg

neg

neg

neg

neg

neg

neg

neg

neg

neg

neg

neg

neg

363

Patient id Clone 3 423 þ .A01 423 þ .A02 423 þ .A05 423 þ .A06 423 þ .A07 423 þ .A11 423 þ .A12 423 þ .B04 423 þ .B05

SF SF SF SF SF SF SF SF SF SF SF SF SF SF SF SF SF SF SF SF SF SF SF SF SF SF SF SF SF SF SF SF SF SF

K. Amara et al. / Data in Brief 13 (2017) 356–370

153 þ.H11 153-.A03 153-.A04 153-.A06 153-.A07 153-.A12 153-.B07 153-.C04 153-.C07 153-.C09 153-.C11 153-.C12 153-.D11 153-.D12 153-.E12 153-.F02 153-.F03 153-.F05 153-.F06 153-.F09 153-.F10 153-.F11 153-.F12 153-.G02 153-.G06 153-.G08 153-.G12 153-.H01 153-.H01 153-.H04 153-.H06 153-.H09 153-.H10 153-.H11

364

Table 2 (continued ) Patient id Clone

VH

DH

JH Ig SC VH-mut. VH CDR3 (aa)

( þ) Length CCP2 CEP-1 cit-vim 60-75 cit-fib 36-52

SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-)

4-39 3-49 3-53 1-46 4-59 3-20 4-4 4-59 4-39 3-21 1-46 3-30 4-48 4-30-2 1-46 1-46 4-4 3-30 3-30-3 3-48 4-59 4-31 1-69 1-69 1-2 4-34 1-2 3-15 4-31 4-39 3-23 3-33 5-51 3-23 3-33 1-18 1-69 3-43 4-31 4-30-4

3-3 5-24 5-18 3-10 1-20 6-13 3-3 3-16 6-13 6-13 1-1 3-16 3-10 3-10 5-18 3-10 3-9 2-15 5-18 6-19 6-19 6-6 2-15 5-24 1-26 3-3 1-26 4-23 2-21 3-10 3-10 3-10 3-22 5-18 3-16 2-2 5-12 6-13 2-21 3-22

6 4 6 2 4 6 6 4 4 4 6 3 4 4 4 4 4 6 5 1 3 4 3 3 3 4 4 4 6 4 4 6 6 4 5 6 5 4 4 4

1 3 0 2 2 1 1 0 1 0 1 1 2 3 2 1 5 3 1 2 1 2 2 1 1 2 2 3 3 1 0 2 2 1 2 3 6 2 2 2

IgA1 IgA1 IgA1 IgA1 IgG2 IgG1 IgG3 IgG1 IgG4 IgG2 IgG1 IgG1 IgG1 IgG1 IgA2 IgG2 IgG1 IgG1 IgA1 IgG4 IgG1 IgM IgG1 IgM IgA1 IgG2 IgA1 IgG1 IgA2 IgA1 IgA1 IgM IgG1 IgG2 IgA1 IgM IgA1 IgG2 IgG1 IgG1

11 22 16 5 10 11 2 6 13 12 4 23 14 12 17 17 6 34 1 6 5 30 8 24 15 9 12 18 12 13 19 4 2 27 3 5 29 9 16 3

ASSITIFGVVKXXXGMDV AREITSRNGYNHFAY ASGGYSYGLDYYYAMDV ARDQSITMVRGGPPDWNFDL AKSSSPYDWNAPKADY SRDVGSSFPPYYSYAMDV AREGVGSTQGPYYYMDV AAEVMNTDGDVDY ARFPAGYAGSWYVDY ASSPSGPGAAVFDY AKESTATIGTPPEVNYYYGMDV ARETNSYAFDI AGVERDYVSH ARVRWGSGSKIDY ARGRGSSYGVTGFDY ARGSGSGSYYNIDY ARDPRRYHILTGHYEGGPSDY AKRTGPVVVSRGGLDV AREGGGYSYADNWFDP ARDLPSRGAVAEDFDL AREDPGQTPSGDGPDDAFDI AARIASRYFDS ASDVARYCSGGSCYSHAFDI ARTGEMATTPNAFDIW ARGWGAAQVVFDM ARRTTAYFDFWSDYYFDS ARGFRSGSYPGY ATVRRSLSPLKY ARFRHWYYYIDV AGLYGDLFPGVMRYFDP ANAGTGYLPFDY ASRGGVGGYYVKDYGMDV ARLRYYYDSSGYYYMNNYYYYYMDV AKDVVDSVMGLPFDY AREGDLIPDRFDP SRVGRVPDAVRYYFYGDV ARDRRGGNRRRENWFDP AAAPGRRFDY ARGSGSGYDLAYCGGDCYFLLDK AAYPGSYYDNSGRHLISPPFDN

18 15 17 20 16 18 17 13 15 14 22 11 10 13 15 14 21 16 16 16 20 11 20 16 13 18 12 12 12 17 12 18 25 15 13 18 17 10 23 22

K. Amara et al. / Data in Brief 13 (2017) 356–370

423 þ .B06 423 þ .B11 423 þ .B12 423 þ .C01 423 þ .C05 423 þ .C07 423 þ .D05 423 þ .D10 423 þ .E01 423 þ .E02 423 þ .E05 423 þ .E08 423 þ .F02 423 þ .F05 423 þ .F10 423 þ .G01 423 þ .G03 423 þ .G07 423 þ .G10 423 þ .G12 423 þ .H08 423 þ .H09 423 þ .H10 423 þ .H11 423-.A02 423-.A05 423-.A09 423-.B01 423-.B10 423-.B11 423-.C02 423-.C03 423-.C04 423-.C05 423-.C09 423-.C12 423-.D01 423-.D02 423-.D03 423-.D06

cell origin

FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-) FcRL4-)

3-48 3-30 3-49 4-61 3-23 3-33 3-11 1-2 5-10-1 3-33 3-9 1-46 1-46 3-30-3 4-31 4-30-4

5-12 3-3 3-10 6-19 2-8 6-13 2-21 3-10 2-15 6-19 3-16 6-19 2-2 6-19 3-10 5-18

3 4 6 4 4 5 4 4 3 4 5 4 4 3 4 6

IgG2 IgG1 IgG1 IgM IgG1 IgG1 IgG1 IgG3 IgG1 IgG1 IgM IgG1 IgG3 IgG1 IgG1 IgG1

20 12 18 6 10 15 22 14 10 32 1 18 12 8 29 19

ARGGYSGYLLTHDAFDI ANEVDFWSGYYDY SRVDRVVRGGRYYYYCMDV ARVPRGWYYIDY AKPLVYARLYFDY ARDPPTSQYSSTWWTDRGFDH AREGPIVVVPVV ASGVNADGEGGPPTVGY AKAASRFDTFDI ARDRQWLLDY AKGGWITLGSWFDP ARVVTDTAGWYHFDY ARGRLPAAIRIDFDY AKDGKAVDGFSGVLEM AGVERDYVSH ARERSYGRQYHYGMDV

2 0 4 2 2 3 1 0 2 2 1 2 3 2 2 4

17 13 19 12 13 21 12 17 12 10 14 15 15 16 10 16

cell origin ST, CD19þ ST, CD19þ ST, CD19þ ST, CD19þ ST, CD19þ ST, CD19þ ST, CD19þ ST, CD19þ ST, CD19þ ST, CD19þ ST, CD19þ ST, CD19þ ST, CD19þ ST, CD19þ ST, CD19þ ST, CD19þ ST, CD19þ ST, CD19þ ST, CD19þ ST, CD19þ ST, CD19þ ST, CD19þ ST, CD19þ ST, CD19þ ST, CD19þ ST, CD19þ ST, CD19þ

FcRL4 þ FcRL4 þ FcRL4 þ FcRL4 þ FcRL4 þ FcRL4 þ FcRL4 þ FcRL4 þ FcRL4 þ FcRL4 þ FcRL4 þ FcRL4 þ FcRL4 þ FcRL4 þ FcRL4 þ FcRL4 þ FcRL4 þ FcRL4 þ FcRL4 þ FcRL4 þ FcRL4 þ FcRL4 þ FcRL4 þ FcRL4 þ FcRL4 þ FcRL4 þ FcRL4 þ

VH 4-59 5-51 5-51 1-3 3-33 3-30-3 3-21 3-48 4-34 1-18 4-34 3-33 1-69 1-69 3-20 3-30-3 3-21 3-33 3-33 3-74 1-3 4-39 1-3 4-39 3-33 4-4 3-20

DH 6-13 3-22 3-10 2-21 4-17 5-12 3-3 5-24 3-22 3-22 6-13 2-15 2-15 1-26 2-2 3-22 1-26 3-10 2-15 6-19 4-17 5-24 2-2 2-8 3-10 3-3 4-17

JH 1 5 3 4 6 4 5 6 4 4 4 5 6 4 4 4 4 6 6 2 6 3 6 4 6 6 4

Ig SC IgA1 IgG2 IgG1 IgG3 IgA1 IgG1 IgA1 IgG1 IgM IgG1 IgG1 IgG1 IgG1 IgG1 IgA1 IgG1 IgG1 IgA2 IgA1 IgG1 IgG3 IgG1 IgG4 IgG1 IgA1 IgG1 IgA1

VH-mut. 1 26 19 25 25 1 4 13 14 13 9 28 4 16 11 10 2 31 24 6 13 10 9 13 29 6 4

VH CDR3 (aa) ARYFFGGMSAAGSYFQH ARLSGYYDSSGYYYPYNWFDS VRHILWFGESDSFDI ARSHQPYILLAGRPGV CAGDYITRPNFSYYYYGMDV AKYHVDIVATSLEYFDY ARVWEDWFDP AKDQPHGHIYYGLDV ARDREYYDSRGYYSFDY AREFPYDSSGYFPGGGDY ARGPPRAVPGTARRRYFDS ARHGRGPSSWYDF ARGYCSGGSCFDHYYYYGMDV ARGFQVGTITGFDY AKSLIGVESSFDS ARGKDYYDSTGYYWGILDD ARDRRVPYIVGATDFDY ARGPSGMFGDLSPYFHYGVDV ARDREAATPKYGMDV AREVEQWLEHGVLWYFDL AGDYITRPNFSYYYYGVDV ARDREMGHQGIFDI SRDRSISWDGDGMDVW ARDKGNQPFFDY ASRGGVGGYYVKDYGVDV ARVSSAKTTFGVTTTWGGMDV ARGGGPGDKVRGDY

( þ) 2 1 2 3 1 2 1 3 3 1 5 3 2 1 1 2 3 2 3 2 1 3 2 2 2 2 3

Length 17 21 15 16 20 17 10 15 17 18 19 13 21 14 13 19 17 21 15 18 19 14 16 12 18 21 14

365

Patient id Clone 2 03þ .A02 03þ .A03 03þ .A09 03þ .B01 03þ .B02 03þ .B03 03þ .B04 03 þ .B05 03þ .B06 03þ .B09 03þ .B09 03þ .C02 03þ .C03 03þ .C10 03þ .C11 03þ .C12 03þ .D02 03þ .D04 03þ .D06 03þ .D07 03þ .D08 03þ .F01 03þ .F03 03þ .F04 03þ .F05 03þ .F07 03þ .F08

(CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ (CD19 þ

SF SF SF SF SF SF SF SF SF SF SF SF SF SF SF SF

K. Amara et al. / Data in Brief 13 (2017) 356–370

423-.E02 423-.E07 423-.E08 423-.E12 423-.F03 423-.F04 423-.F06 423-.F07 423-.F10 423-.G03 423-.G05 423-.H03 423-.H04 423-.H06 423-.H07 423-.H11

366

Table 2 (continued ) Patient id Clone

Patient id Clone 6 508 þ .A05 508 þ .A07 508 þ .A10 508 þ .B03

VH

DH

JH Ig SC VH-mut. VH CDR3 (aa)

( þ) Length CCP2 CEP-1 cit-vim 60-75 cit-fib 36-52

ST, CD19þ FcRL4 þ ST, CD19þ FcRL4 þ ST, CD19þ FcRL4 þ ST, CD19þ FcRL4 þ ST, CD19þ FcRL4 þ ST, CD19þ FcRL4 þ ST (CD19þ FcRL4-) ST (CD19þ FcRL4-) ST (CD19þ FcRL4-) ST (CD19þ FcRL4-) ST (CD19þ FcRL4-) ST (CD19þ FcRL4-) ST (CD19þ FcRL4-) ST (CD19þ FcRL4-) ST (CD19þ FcRL4-) ST (CD19þ FcRL4-) ST (CD19þ FcRL4-) ST (CD19þ FcRL4-) ST (CD19þ FcRL4-) ST (CD19þ FcRL4-) ST (CD19þ FcRL4-) ST (CD19þ FcRL4-) ST (CD19þ FcRL4-) ST (CD19þ FcRL4-) ST (CD19þ FcRL4-) ST (CD19þ FcRL4-) ST (CD19þ FcRL4-) ST (CD19þ FcRL4-) ST (CD19þ FcRL4-) ST (CD19þ FcRL4-) ST (CD19þ FcRL4-) ST (CD19þ FcRL4-) ST (CD19þ FcRL4-) ST (CD19þ FcRL4-)

3-66 1-69 1-69 1-3 4-4 4-34 3-9 1-69 3-23 1-69 1-69 4-59 1-18 3-23 3-53 3-49 3-23 4-34 3-30-3 3-21 4-30-4 3-23 3-74 3-23 3-23 3-23 3-11 3-23 3-30 4-39 3-20 3-7 4-31 3-33

2-2 6-19 6-13 2-8 3-22 4-23 2-15 2-21 6-13 5-24 6-13 3-10 2-2 1-26 3-16 4-17 3-22 2-8 3-3 3-22 3-3 3-22 3-3 2-8 3-9 5-24 3-22 3-10 1-26 5-24 3-22 3-9 3-10 3-3

6 6 5 4 4 6 4 6 4 3 4 4 4 6 6 5 1 4 4 3 4 4 5 4 4 4 4 6 4 5 4 5 5 4

ARGGTISRYYYFGMDV ARGAVAGRHYYFGLDV TREAAAAGRNNWFDP ARSHQPYILLAGTPGD CACRYLGLDY CARVPEVVTPRYYYYFGLDV VKDGGAGGANTFDH ASKGGDSVGYHYYMDV AKGPYSSSWYGAPFDY ARDREMGHQGIFDI ARARIAAAGNPGSFDY ARDSSYEDSVYFDY ARDEFQLPDY AKSWAILQFEPLYGMDV TRERPHEYVWGSFRRHYGMDV TIVFPELPRVPLP AKDRAGNNSGYYYVGEYFQH ARGRETYCAAGVCSSKGKRPDYFDY AREFEHFGSGYFPVDY ARDRFPSDDYDGPEGFDL ARASTLEWSYGSFDY AKADYSDSSGYKDY ASSYRIWSFDP AKPMVYARLYFDY AKDFTRYFDWLLRDLFDY ARDRMACDY ARDLTGMNSDSSGYYSDY AKAGQSPDMVRGVIRWGPKPEPKNSYYGMDV AKGVGALQAGLGSGVYYFNY ARRGHYVWFDP ARGPPYYISSGYYFSFDS ARTPGTFHTHNWFDP ARVVPAHHFPSGGHSSSAFNWFDP TRSLGYCTRSTCYSHEHYDH

2 3 2 2 1 2 2 2 1 3 2 1 1 1 6 1 3 5 2 2 1 2 1 2 3 2 1 5 1 3 1 3 4 5

16 16 15 16 10 20 14 16 16 14 16 14 10 17 21 13 20 25 16 18 15 14 11 13 18 9 18 31 20 11 18 15 24 20

cell origin SF (CD19 þ SF (CD19 þ SF (CD19 þ SF (CD19 þ

VH 1-8 3-66 3-7 3-11

DH 2-15 3-9 3-10 3-10

JH Ig SC VH-mut. 5 18 4 15 6 32 6 0

VH CDR3 (aa) ARGHGHCSDSGCFNNWFDP ARSPTGYDILTGPFDY ARDNARAWFSHYYYGMDV ARDLRYYGSGMYYTYYYYGMDV

( þ) 3 1 3 2

Length 19 16 18 22

FcRL4-) FcRL4-) FcRL4-) FcRL4-)

IgA1 IgA1 IgG2 IgG2 IgG4 IgG1 IgG3 IgG1 IgA1 IgG1 IgG1 IgG1 IgG4 IgG1 IgG1 IgA1 IgG2 IgG1 IgA2 IgG2 IgG1 IgG1 IgG1 IgA1 IgG1 IgG1 IgG2 IgG1 IgA1 IgM IgM IgA1 IgG1 IgA1

1 19 4 13 18 9 33 29 7 22 4 4 4 28 15 29 14 4 31 30 29 19 13 1 19 15 18 22 23 25 8 6 25 15

K. Amara et al. / Data in Brief 13 (2017) 356–370

03þ .G03 03þ .G07 03þ .G08 03þ .G12 03þ .H01 03þ .H04 03-.A01 03-.A02 03-.A03 03-.A04 03-.A06 03-.A08 03-.A12 03-.B06 03-.B11 03-.C01 03-.C03 03-.C05 03-.C08 03-.C09 03-.D04 03-.D05 03-.D07 03-.D08 03-.D11 03-.E07 03-.E08 03-.E11 03-.F08 03-.F10 03-.G07 03-.G11 03-.H04 03-.H10

cell origin

3-33 3-11 4-31 3-30 3-74 1-69 3-48 4-34 3-30 3-11 3-15 1-46 3-7 1-8 3-21 1-8 1-24 3-48 3-33 3-23 3-15 4-61 4-30-4 3-48 3-30 1-69 4-34 1-18 3-43 1-24

3-10 3-10 3-3 6-6 3-3 5-18 6-13 4-11 3-10 3-9 3-16 2-15 2-21 3-10 5-12 3-3 2-15 2-8 2-2 6-19 3-3 2-2 5-12 5-18 4-17 4-11 7-27 6-19 3-22 3-9

6 6 4 4 1 5 5 6 5 6 2 4 4 4 5 4 4 5 6 4 4 4 4 3 5 4 4 4 6 4

Patient id Clone 4 531þ .A01 531þ .B07 531þ .B08 531þ .B09 531þ .C02 531þ .C07 531þ .C08 531þ .C12 531þ .D03 531þ .G01 531þ .G02 531þ .G03 531þ .G04

cell origin SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4þ ) SF (CD19 þ FcRL4þ ) SF (CD19 þ FcRL4þ ) SF (CD19 þ FcRL4þ ) SF (CD19 þ FcRL4þ ) SF, CD19 þ FcRL4þ SF (CD19 þ FcRL4þ ) SF (CD19 þ FcRL4-) SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ

VH 3-21 3-74 4-39 4-39 1-18 3-33 4-34 3-9 4-34 1-69 1-3 3-33 3-15

DH 1-1 3-10 4-17 3-3 2-2 6-19 6-6 1-1 1-26 6-13 3-10 4-17 6-19

JH Ig SC VH-mut. 4 15 4 28 2 6 6 11 4 15 2 19 4 17 4 22 3 5 6 28 4 23 4 3 6 15

28 33 18 20 19 21 28 12 19 3 10 12 17 17 28 29 9 14 13 7 13 17 4 17 5 4 4 4 36 4

ASRGGVGGYYVKDYGMDV ARMWFGDDHYYYGLDI ARGQRGAILVHGYIPFFDF AKDPHSSSLISPPLFGY ARVFKGWSSWYQGSPSEYFQH ARGRTYTYGPMRWFDP ARGQGRIEYNWFDL ARPTHSTVTMWYFGMDV ARDPINYYGSGSYSWNWIDP ASPSGNPNPFTMDV AREVTPHWYFDL ARGGPFTNPLCSASTCYYFDS ARAADYGPVAGLFEY AFHLGEYGSGSYYDLDY ARVWVTGAAIFGDNWFDP ARAAVDFWSGYHLEY AIMGALYCSGGDCYLRGAGEFDY ARGLGRLCGADNCYNWFDP ARARYSSSSYGMDV AREGIPVAGTDY TAYRITPFGVLTGFGERPVDY ARIKGGYCSYTNCKRPVPFDY ATAPRSPTGYDSFYLDS ARGRKGYSYDAFDI AQDRVAALTRGGLGWFDP ARELYSNYFF ARLRPRLRGDLDS ARTTGGDSGWFDHMDF AKGLRKTDVYYDSSGFGYYYGMDV ATENRFRHFWYGFDF

2 2 3 2 3 3 2 2 1 0 2 1 1 1 1 2 1 2 2 1 2 4 1 3 2 1 4 2 3 3

18 16 19 17 21 16 14 17 20 14 12 21 15 17 18 15 23 19 14 12 21 21 17 14 18 10 13 16 24 15

VH CDR3 (aa) ARCRPGSTSPEF ARERSRIIDY TRQWGSDYGDYWYFDL SRDQRITILGVVSVWFGMDV ARALLDGYCTGSSCAVGSMDY AGSLSSGWHGNRYFDL AKGSTSSLYRHTMPYQY ARDAKYYFDY ARSWELLLGAFDI ATAGYTSRWNPSFYHGLDV ARDYGSGNSGYFDY VTDYGDYVELGY ARGWLEPFYYYGVDV

( þ) 2 3 1 2 1 2 3 2 1 2 1 0 1

Length 12 10 16 20 21 16 17 10 13 19 14 12 15

367

SF, CD19 þ FcRL4þ SF (CD19 þ FcRL4þ ) SF (CD19 þ FcRL4þ ) SF, CD19 þ FcRL4þ SF (CD19 þ FcRL4þ ) SF (CD19 þ FcRL4þ ) SF (CD19 þ FcRL4þ ) SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-)

K. Amara et al. / Data in Brief 13 (2017) 356–370

508 þ .D05 508 þ .D11 508 þ .E03 508 þ .E06 508 þ .E09 508 þ .E10 508 þ .E11 508 þ .F02 508 þ .F04 508 þ .F09 508 þ .F11 508 þ .F12 508-.B04 508-.B09 508-.B10 508-.C04 508-.C07 508-.D06 508-.D08 508-.D10 508-.E12 508-.F03 508-.F08 508-.G05 508-.G08 508-.G09 508-.H07 508-.H08 508-.H11 508-.H12

368

Table 2 (continued ) Patient id Clone

VH

DH

JH Ig SC VH-mut. VH CDR3 (aa)

( þ) Length CCP2 CEP-1 cit-vim 60-75 cit-fib 36-52

SF, CD19 þ FcRL4þ SF, CD19 þ FcRL4þ SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-) SF (CD19 þ FcRL4-)

3-11 4-4 3-23 1-46 3-69 3-48 3-23 4-4 3-11 3-23 3-33 4-34 3-48 1-2 4-31 3-23 1-18 4-31

3-10 5-12 3-3 3-3 1-26 3-16 4-23 2-15 5-18 5-18 3-16 3-3 3-22 3-22 4-11 6-19 3-3 3-10

5 6 6 6 4 4 4 4 4 4 5 4 4 3 6 4 3 3

2 2 2 2 4 1 1 1 4 3 3 4 1 2 1 1 1 2

15 19 25 14 3 22 2 23 15 4 1 25 5 3 2 9 9 12

ARDLLVHGVAISNWFDP ARYSGFYYHYGMDV AKGGSGAFWSGYYKNYYYYYMDV ARVTFESNDFGPDHFYYVLDV ARHNGSYKKGYYFDY AGGRSYDYFDY AKEVQTEGGFDY ARVVSEAAYFDN ARRGGYSYRKDYFDS AKDKWEGAMNPHYFDF ARETFERIRLGEPNWFDP TRDLSRKIFGVVKPAFYFDY AREGEGDLYYYDSSGYYYL ASKKEGVLPLDPFDI GRTLATVPMDV AKGSVAGPFDY ARAEGAVTIDDAFDI ARDGAGRDAFDM

17 14 23 21 15 11 12 12 15 16 18 20 19 15 11 11 15 12

K. Amara et al. / Data in Brief 13 (2017) 356–370

531þ .G11 531þ .H07 531-.D10 531-.D11 531-.D12 531-.E01 531-.E02 531-.E03 531-.E09 531-.E12 531-.F02 531-.F03 531-.F05 531-.F07 531-.G03 531-.G11 531-.H07 531-.H08

cell origin

Table 3 Number of sequences and recombinant monoclonal antibodies generated from FcRL4þ and FcRL4- B cells respectively. Sample

Diagnosis

CCP2

RF

FcRL4

Number of sorted 96-well plates

Number of retrieved sequences

Number of ab cloned

Number of ab. expressed

1

ST

RA

pos

pos

2

ST

RA

pos

pos

3

SF

RA

neg

neg

4

SF

RA

neg

neg

5

SF

RA

pos

pos

6

SF

RA

na

pos

positive negative positive negative positive negative positive negative positive negative positive negative

1 1 1 1 1 1 1 1 1 1 1 1

59 33 33 28 33 32 15 16 30 33 16 18

34 23 ND ND ND ND ND ND 22 25 ND ND

26 17 ND ND ND ND ND ND 10 10 ND ND

K. Amara et al. / Data in Brief 13 (2017) 356–370

Patient ID

369

370

K. Amara et al. / Data in Brief 13 (2017) 356–370

primed reactions. Library prep was carried out using the Illumina TruSeq Stranded prep kit and sequenced on the Illumina HiSeq. 2000/2500 platform. Data were analysed as detailed in [1].

Acknowledgements We are grateful for excellent technical assistance from Peter Sahlström (KI) and Holly Adams (Birmingham). This study was supported by grants from the Karolinska Institutet Foundations for Rheumatology Research, (2014reum42676) the Nanna Svartz foundation (2015-00077), the Knut and Alice Wallenberg foundation, the Swedish research council (VR) (2012-02677 and 2015-02900), the Swedish association against rheumatism, the Börje Dahlin Foundation, the King Gustaf V 80-year Foundation, the Ulla and Gustaf af Ugglas Foundation (2014uggl42674), and the VR-supported Linneaus consortium (CERIC) (2007-8703) to VM and KA. Furthermore, this work was supported by MRC DPFS grant code MR/M007669/1 to DS-T as well as a Wellcome Trust ISSF (097825/Z/11/A) grant. We received funding from European Community's Collaborative project FP7-HEALTH-F2-2012-305549 “EURO TEAM”. AF was supported by an Arthritis Research UK Clinician Scientist Award 18547. The Arthritis Research UK Rheumatoid Arthritis Pathogenesis Centre of Excellence – RACE, - is partfunded by Arthritis Research UK through grant number 20298.

Transparency document. Supporting information Transparency data associated with this article can be found in the online version at http://dx.doi. org/10.1016/j.dib.2017.06.009.

Reference [1] K. Amara, E. Clay, L. Yeo, D. Ramsköld, J. Spengler, N. Sippl, J.A. Cameron, L. Israelsson, P.J. Titcombe, C. Grönwall, I. Sahbudin, A. Filer, K. Raza, V. Malmström and D. Scheel-Toellner, B cellscells expressing the IgA receptor FcRL4 participate in the autoimmune response in patients with rheumatoid arthritis, J. Autoimmun. 2017 Jul;81:34-43. doi: http://dx.doi.org/10. 1016/j.jaut.2017.03.004. Epub 2017 Mar 24. Epub 2017 Mar 24. (Epub ahead of print)(GEO link to RNAseq dataset from sorted FcRL4 þ and FcRL4- synovial fluid B cells: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc ¼ GSE94897).